Evidence map›Paper›PMID 24318084›Full record

ArticleQuality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation2014

Quality of life assessed with EQ-5D in patients undergoing glioma surgery: what is the responsiveness and minimal clinically important difference?

Lisa Millgård Sagberg, Asgeir S Jakola, Ole Solheim

Abstract readValidation Study
PubMed Publisher
In one paragraph

Article in Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 6 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 6 syntheses or guidelines pooled it.

  1. A systematic review of minimum important changes for generic multi-attribute utility instruments and recommendations for their estimation.The European journal of health economics : HEPAC : health economics in prevention and care · 2025
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Cancer-specific utility: clinical validation of the EORTC QLU-C10D in patients with glioblastoma.The European journal of health economics : HEPAC : health economics in prevention and care · 2025
    Trial
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Associations between financial toxicity, health-related quality of life, and well-being in Indonesian patients with breast cancer.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2025
    Article
  14. Review
  15. Article
  16. The EORTC QLU-C10D is a valid cancer-specific preference-based measure for cost-utility and health technology assessment in the Netherlands.The European journal of health economics : HEPAC : health economics in prevention and care · 2024
    Article
  17. Observational
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Lisa Millgård SagbergDepartment of Neuroscience, Norwegian University of Science and Technology, 7491, Trondheim, Norway, lisa.millgard.sagberg@ntnu.no.
Asgeir S Jakola
Ole Solheim

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo evaluate the responsiveness of EQ-5D 3L in patients undergoing intracranial glioma surgery and estimate the minimal clinically important difference (MCID). MATERIALS AND

methodsEQ-5D 3L index values from 164 patients who underwent glioma surgery in the period 2007-2012 were analysed. Responsiveness and MCID were estimated using a combination of distribution-based and anchor-based methods. Karnofsky performance status served as an anchor.

resultsPatients who improved functionally did not report significantly higher EQ-5D 3L scores post operatively with a standardized response mean (SRM) of 0.04 (p = 0.13). Patients who deteriorated functionally reported significantly lower EQ-5D 3L scores post operatively with a SRM of 0.72 (p < 0.001). With different approaches, we determined a range of MCID values from 0.13 to 0.15.

conclusionsEQ-5D 3L is responsive to changes when glioma patients are deteriorating functionally after surgery but not responsive when the patients are improving. The MCID values for EQ-5D 3L in glioma surgery seem higher than reported MCID values for other types of cancers.

Indexed as

Brain NeoplasmsChemotherapy, AdjuvantCross-Sectional StudiesDrug-Related Side Effects and Adverse ReactionsFemaleGliomaHealth Status IndicatorsHumansKarnofsky Performance StatusLongitudinal StudiesMaleMiddle AgedNeoplasm GradingNorwayPostoperative PeriodProspective Studies

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.